Company intelligence / Profile preview
Louis Falo
Pittsburgh, Pennsylvania, United Statesskinject.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SkinJect is a clinical-stage biopharmaceutical company developing a novel, minimally invasive treatment for non-melanoma skin cancer. Founded by Dr. Louis Falo and Dr. O. Burak Ozdoganlar, the company utilizes a proprietary dissolvable microneedle array (MNA) platform to deliver chemotherapeutic agents directly into the tumor site. Their lead candidate, SKJ-1011, delivers doxorubicin to treat basal cell carcinoma, aiming to provide an efficacious alternative to surgical excision. The technology is designed to improve patient outcomes by reducing scarring and clinical burden while ensuring localized drug delivery.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Small moleculeDeviceMicro-needle arrayDissolvable microneedle
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of PittsburghCarnegie Mellon University
Beyond the preview
Go deeper on Louis Falo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Louis Falo.